news nestle moves into gut microbiome testscrispr patent estate splintersswiss food giant nestle has entered a partnership with french biotech enterome biosciences to develop microbiome-based diagnostics for inflammatory bowel disease ibd and non-alcoholic fatty liver disease nafld.

the microbiome diagnostic partners mdp announced on july 11 consists of a 5050 joint venture between the paris-based enterome and nestle health science the epalinges switzerland-based nestle subsidiary.

in april 2016 nestle formed part of a 14.5-million series c roundto develop enterome's eb 8018--a novel small- molecule fimh antagonist that targets adherent invasive escherichia coli proliferation in the gut one of the main causes of ibd.nestle gains options to exclusively license rights to commercialize the two initial programs and nestle's diagnostics subsidiary san diego- based prometheus laboratories will bring in development and commercialization expertise to mdp to develop a biomarker and diagnostic.also on july 11 google-backed cambridge massachusetts-based evelo biosciences raised a total 100 million with plans to begin fiveto ten clinical trials of monoclonal microbes-- specific single strains of naturally occurring microbes--in 2018 followed by licensing a microbiome-based cancer immunotherapy from the university of chicago in april 2016.the long-running crispr-cas9 patent dis-pute over rights to the lucrative gene-editing tool has taken a new turn with the european patent office announcing its intention to award merck kga a patent for the technol- ogy.

nestle will invest eur20 22.8 million in the mdp and paris-based enterome will grant exclusive rights to its microbiome profiling tests in all areas except immuno-oncology.

